Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
•
Medical Oncology
•
Breast Cancer, Metastatic
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
Any pitfalls to be aware of?
Answer from: Medical Oncologist at Community Practice
Yes. Follow CBC
Sign In
or
Register
to read more
22945
Related Questions
What are your top takeaways in Medical Oncology from SABCS 2024?
What are your top takeaways in Radiation Oncology from SABCS 2024?
How do you manage a symptomatic primary breast tumor in a patient with metastatic disease?
What are your top takeaways in Breast Cancer from ASCO 2025?
What are your top takeaways in Breast Cancer from ESMO 2025?
What is your preferred comprehensive nodal irradiation approach in non-metastatic breast cancer patients with underlying respiratory diseases or poor baseline respiratory function in light of the findings from the RadComp Trial?
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
For patients with HbA1c >6 can the INAVO regimen still be utilized if the patient is otherwise fit and has a strategy for ongoing glycemic control?
Is the currently available data from INAVO sufficient to adopt this as a new standard of care for all patients or are you awaiting overall survival and/or PROs?
How does the safety profile of Dato-DXd influence its use in patients with comorbidities or frailty compared to standard chemotherapy?